Kilitch Drugs India Ltd (KILITCH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Kilitch Drugs India Ltd on NSE and BSE, with an AI summary of each filing.
KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 06 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 06 Nov 2026, 5:30 am
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve unaudited standalone and ....
Intimation · 06 Nov 2026, 5:30 am
Kilitch Drugs Schedules Board Meeting to Approve Q2 FY27 Financial Results Kilitch Drugs (India) Limited will hold its Board of Directors meeting on 6th Nov'26 to consider and approve unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed since 1st Oct'26 and will reopen 48 hours post the formal dissemination of the financial results to stock exchanges.
We are hereby submitting the Notice of EGM
Extra Ordinary General Meeting · 23 Oct 2026, 10:45 pm
Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval Kilitch Drugs (India) Ltd. has convened an EGM on 16th Nov'26 to approve the divestment of its entire stake in Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to HarmeeCare Pharmaceuticals. Prior to the sale, Kilitch will convert up to INR 57.00 crore of outstanding debt into KEB equity, raising its holding from 67.00% to 89.17%. The total transaction value is USD 14.00M, with Kilitch receiving USD 12.855M. Net proceeds will fund loan repayments, interest reduction, and expansion of its Pen manufacturing facility in India.
We are enclosing herewith the press release
Press Release · 23 Oct 2026, 8:45 pm
Kilitch Drugs Divests Ethiopian Arm for $14 Million to Fund Expansion Kilitch Drugs (India) announced on 23rd Oct'26 that it will divest its entire stake in Ethiopian subsidiary Kilitch Estro Biotech PLC to state-owned HarmeeCare Pharmaceuticals for US$14 million, targeted for completion by 31st Jan'27. The company will retain a commercial presence in Ethiopia via a long-term supply and technical services pact. Net proceeds will fund debt reduction and the phased expansion of its Pen, Maharashtra facility for injectables, ophthalmic drops, and GLP-1 therapies targeting regulated export markets under EU GMP and PIC/S standards.
Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary into equity shares Appointment of Additional independent non-executive director
Others (Uncategorized) · 23 Oct 2026, 1:48 am
Kilitch Drugs Divests Ethiopian Subsidiary For USD 12.86M Following Debt-To-Equity Conversion Kilitch Drugs' board approved divesting its entire stake in Ethiopian subsidiary Kilitch Estro Biotech PLC (KEB) to state-owned HarmeeCare Pharmaceuticals for USD 14.0M total consideration, with USD 12.86M due to the company. Target completion is 31st Jan'27. Prior to divestment, Kilitch will convert up to INR 57.00 Cr outstanding debt into 1,66,472 KEB equity shares at Rs. 3,414 each by 30th Dec'26. In FY26, KEB contributed INR 47.57 Cr revenue (20.20% of consolidated) and negative INR 8.43 Cr net worth.
We hereby inform you that Mr. Venkita Subramanian Rajan has tendered his resignation from the position of Non-executive Independent Director of the Company with immediate effect
Change in Management · 21 Oct 2026, 7:31 pm
Kilitch Drugs Announces Immediate Resignation of Independent Director Venkita Subramanian Rajan Kilitch Drugs (India) Ltd. announced the resignation of Mr. Venkita Subramanian Rajan from his position as Non-Executive Independent Director, effective 21st Oct'26. The resignation is attributed to pre-occupation and other personal commitments, with confirmation that no other material reasons exist. Consequently, Mr. Rajan also ceases to serve as Chairman and Member across the company's Audit Committee, Nomination and Remuneration Committee, and Stakeholder Relationship Committee.
We are submitting herewith the scrutinizer''s report for the voting process of 34th Annual General Meeting of Kilitch Drugs India Limited
Annual General Meeting · 27 Aug 2026, 11:53 pm
We are submitting herewith the proceeding of 34th Annual General Meeting
Annual General Meeting · 27 Aug 2026, 10:01 pm
We are submitting herewith the monitoring agency report
Others (Uncategorized) · 19 Aug 2026, 4:47 am
Kilitch Drugs: Monitoring Report on Rs. 49.92 Crore Rights Issue Kilitch Drugs (India) Ltd. has submitted the monitoring agency report for the quarter ended 30th Jun'26, concerning its Rs. 49.92 crore rights issue. As of the quarter's end, the entire net proceeds of Rs. 49.45 crore were fully utilized. Rs. 47.00 crore were allocated to the Greenfield Project in Pen, Maharashtra, and Rs. 2.45 crore for General Corporate Purposes (GCP). The report confirms no deviation from the issue's stated objectives. A minor delay in GCP utilization was noted, with Rs. 1.12 crore utilized in Q1FY27.
Submission of financial results for the quarter ended 30th June 2026
Outcome · 14 Aug 2026, 2:34 am
Kilitch Drugs Q1FY27 Standalone PAT Grows 5.4% YoY Kilitch Drugs reported Q1FY27 standalone results with revenue at ₹4,091.20 lakh, up 19.9% YoY but down 43.2% QoQ. Net profit rose 5.4% YoY to ₹505.24 lakh but declined 64.0% QoQ. Total Comprehensive Income stood at ₹1,005.46 lakh, up 30.1% YoY. On a consolidated basis, revenue was ₹4,487.89 lakh (+4.0% YoY) and net profit after tax attributable to owners was ₹291.30 lakh, a 10.3% YoY decline. The board approved these unaudited results for the quarter ended 30th Jun'26.
We are submitting herewith the financial results for the quarter ended 30th June 2026
Financial Result · 14 Aug 2026, 2:22 am
Kilitch Drugs India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 4,488 (+4.0% YoY | -49.9% QoQ) ■ EBITDA: 294 (-10.1% YoY | -86.7% QoQ) ■ EBITDA Margin (%): 6.5 (-103 bps YoY | -1817 bps QoQ) ■ PAT: 291 (-3.7% YoY | -79.9% QoQ) ■ EPS (INR): 0.83 (-11.7% YoY | -80.4% QoQ)
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve unaudited standalone and ....
Intimation · 13 Aug 2026, 5:30 am
Kilitch Drugs to Announce Q1FY27 Results on 13-Aug-26 Kilitch Drugs (India) Ltd. has scheduled a Board of Directors meeting on 13-Aug-26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30-Jun-26. In accordance with insider trading regulations, the trading window for designated persons has been closed from 1-Jul-26 and will reopen 48 hours after the financial results are publicly disclosed. The announcement is pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015.
We are submitting the copy of Physical intimation made to the shareholders whose email address was not registered
Annual General Meeting · 02 Aug 2026, 1:12 am
Kilitch Drugs Sets FY26 Annual General Meeting for 27th Aug'26 Kilitch Drugs (India) Ltd. has scheduled its 34th Annual General Meeting (AGM) for Thu, 27th Aug'26, at 9:00 AM IST, to be conducted via video conferencing. The company has published its FY25-26 Annual Report and AGM notice, available on its website. Shareholders without registered email addresses as of the 24th Jul'26 cut-off date have been notified via physical letters. The company also reminded physical security holders to update their KYC details and dematerialise their shares per SEBI circulars.
We are submitting the intimation of Book Closure
Others (Uncategorized) · 02 Aug 2026, 1:05 am
Kilitch Drugs Announces AGM and Book Closure Dates for Aug'26 Kilitch Drugs (India) Ltd. has scheduled its 34th Annual General Meeting for Thu, 27th Aug'26, at 9:00 a.m. via video conferencing. The company announced a book closure from 20th Aug'26 to 27th Aug'26, inclusive. The cut-off date for determining member eligibility for the AGM notice was 24th Jul'26. The record date for determining voting rights for the AGM, including e-voting, is set for 20th Aug'26. The announcement applies to both NSE (KILITCH) and BSE (524500) listings.
We are submitting herewith the annual report for the FY 2025-26
Others (Uncategorized) · 02 Aug 2026, 12:47 am
We are hereby submitting the notice of Annual General Meeting schedule to be held on Thursday, 27th August, 2026
Annual General Meeting · 02 Aug 2026, 12:25 am
Outcome of board meeting is enclosed for ready reference
Others (Uncategorized) · 28 Jul 2026, 11:29 pm
Kilitch Drugs Board Approves AGM, Re-appoints Cost Auditors Kilitch Drugs’ board, in its meeting on 28th Jul'26, approved key corporate actions. The 34th Annual General Meeting for FY26 is scheduled for 27th Aug'26, to be held via video conference. The company has set the record date with the Register of Members to be closed from 20th Aug'26 to 27th Aug'26. Additionally, the board approved the re-appointment of M/s Arvind Kumar & Co., Cost Accountants, as Cost Auditors for the financial year 2026-27.
We are pleased to inform you that we have commenced the Nutraceutical Manufacturing Block of our new plant located at 24/2/1/1 Maldev, Pen, Raigad, Maharashtra India today. i.e 17th June, 2026
Others (Uncategorized) · 17 Jun 2026, 7:43 pm
Kilitch Drugs Commences Production at New Nutraceutical Plant Kilitch Drugs (India) Ltd. announced the commencement of operations at its new Nutraceutical Manufacturing Block on 17th Jun'26. The new plant is located in Maldev village, Raigad district, Maharashtra. This operational launch marks a key development for the company's manufacturing capabilities.
We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 2026
Outcome · 16 May 2026, 12:41 am
Kilitch Drugs (India) Ltd. - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 8960 (+46.3% YoY | +66.5% QoQ) ■ EBITDA: 2214 (+51.7% YoY | +260.0% QoQ) ■ EBITDA Margin (%): 24.7 (+88 bps YoY | +1328 bps QoQ) ■ PAT: 1452 (+39.6% YoY | +227.6% QoQ) ■ EPS (INR): 4.24 (-34.5% YoY | +239.2% QoQ)
We are hereby submitting audited standalone and consolidated financial results for the quarter ended 31st March, 2026
Financial Result · 16 May 2026, 12:35 am
KILITCH DRUGS (INDIA) LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 8960 (+46.3% YoY | +66.5% QoQ) ■ EBITDA: 2214 (+51.7% YoY | +260.0% QoQ) ■ EBITDA Margin (%): 24.7 (+88 bps YoY | +1328 bps QoQ) ■ PAT: 1452 (+39.6% YoY | +227.6% QoQ) ■ EPS (INR): 4.24 (-34.5% YoY | +239.2% QoQ)
We are hereby submitting the monitoring agency report for the quarter ended 31st March, 2026
Others (Uncategorized) · 16 May 2026, 12:19 am
Kilitch Drugs Rights Issue: Capex Utilization and Fund Status Update for Q4FY26 For the quarter ended 31 Mar'26, Kilitch Drugs utilized ₹7.37 crore from its ₹49.92 crore rights issue, with ₹6.65 crore for its Greenfield Project and ₹0.72 crore from the GCP fund for capex. Total funds utilized stand at ₹48.33 crore. ₹1.12 crore remains unutilized from the General Corporate Purpose allocation, with deployment delayed to Q1FY27 pending final project inspection. The unutilized amount is invested in a Kotak Bank FD yielding 6.35%, valued at ₹1.20 crore as of quarter-end.
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the audited financial results ....
Intimation · 15 May 2026, 5:30 am
Kilitch Drugs Sets Board Meeting for Q4 & FY26 Results Kilitch Drugs (India) Ltd. has scheduled a Board of Directors meeting on 15th May'26 to consider and approve its audited standalone and consolidated financial results for the quarter and year ended 31st Mar'26. In accordance with SEBI regulations, the trading window for insiders has been closed since 1st Apr'26 and will reopen 48 hours after the financial results are publicly disclosed. This meeting is a key event for the company's full-year financial performance assessment.
Board approved the allotment of bonus equity shares in the ratio of 1:1
Others (Uncategorized) · 25 Mar 2026, 5:50 pm
Kilitch Drugs Board Approves 1:1 Bonus Share Allotment Kilitch Drugs’ Board on 25th Mar'26 approved the allotment of 17,480,782 bonus equity shares of Rs. 10 face value in a 1:1 ratio. The record date for the issuance was 24th Mar'26. Following the allotment, the company's paid-up share capital has doubled, increasing from 17,480,782 shares to 34,961,564 shares. The new bonus shares will rank pari-passu with existing equity shares.
We hereby inform you that the Company has fixed Tuesday, 24th March, 2026 as record date in order to determine the number of shareholders entitled for bonus equity shares in the ratio of 1:1
Bonus Issue · 17 Mar 2026, 8:50 pm
Kilitch Drugs Announces Record Date for 1:1 Bonus Share Issue Kilitch Drugs (India) Ltd. has fixed 24th Mar'26 as the record date to determine shareholder eligibility for a bonus equity share issue. The company will issue shares in a 1:1 ratio, meaning one bonus equity share of Rs. 10/- will be granted for every one existing equity share held. The deemed date of allotment for the bonus shares is set for 25th Mar'26. Shareholders registered by the close of business on the record date will be entitled to receive the bonus shares.